How genes, gut bacteria and habits affect tirzepatide treatment in obesity
Studies how genes, gut bacteria and behavior relate to tirzepatide treatment in adults with obesity.
Plain-language title generated from the registry record
Registry title: Genetic, Microbiological and Behavioral Factors in Obesity
Key facts
- Where
- Krakow and Warsaw, PolandSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07650149, who can take part
Where in Poland
- Waga ZmianyKrakow, PolandTaking people
- Luxmed sp zooWarsaw, PolandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Jan Kochanowski University
- Trial code
- NCT07650149
- Record updated
- 23 September 2026
- Original description
This study will assess the impact of genetic markers, microbiological (microbiome) and behavioral factors on tolerance, adherence and effectiveness of dual GLP1/GIP RA in the treatment of obesity.Read full original descriptionShow less
OPTIMIZE GEN - Outcomes of Persistence and Treatment With tIrzepatide deterMined by Genetic, mIcrobiological & bEhavioral Factors in obEsity
This study will assess the impact of genetic markers, microbiological (microbiome) and behavioral factors on tolerance, adherence and effectiveness of dual GLP1/GIP RA in the treatment of obesity.
200 consecutive patients who meet all inclusion and none of the exclusion criteria will be enrolled.
Inclusion: Age 18-65 years; Consent to participate in the study and providing informed written consent; Overweight or obese with a BMI >27.
Exclusion: Taking immunosuppressive medications, steroids, NSAIDs, antibiotics (within 2 weeks prior to sample collection),; Type 1 or type 2 diabetes; Cancer; Heart failure; Autoimmune and inflammatory diseases, acute infectious diseases, AIDS, tuberculosis; Mental illness; Alcohol dependence syndrome; Post-myocardial infarction or stroke; Contraindications to tirzepatide use:; Pregnancy or breastfeeding; Expected lack of patient compliance; Liver cirrhosis.